Basel, Switzerland & Princeton, NJ, USA, November 10, 2023 ─ Ymmunobio, a global preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies, has closed its round of seed funding.
Ymmunobio has raised $1.4M to progress both assets, YB-200 and YB-800, to IND-enabling studies.
YB-200, is a humanized anti CEACAM1 antibody with a new mechanism of action, which includes a direct immune agonistic effect on immune cells in addition to the known check-point inhibitor effect.
YB-800 is a first in class humanized antibody targeting the Neuronal Pentraxin Receptor (NPTXR), which is selectively expressed on tumor cells. Both antibodies are developed for treatment of gastrointestinal tumors. YB-200 has received orphan drug status by the US FDA for the treatment of liver cancer in February 2023.
Caroline Germa, MD, board member of Ymmunobio, CMO of Transcenta and former head of early oncology development of Astra Zeneca: “Developing new and first in class antibodies for the treatment of cancers is a critical need. Available preclinical data of YB-200 and YB-800 show that each has the potential to be a first- and/or best-in-class therapy across a broad range of solid tumors.”
Ymmunobio would like to thank its private investors for enabling the advancement of the development of YB-200 and YB-800 to IND enabling studies.
ABOUT YMMUNOBIO
Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making significant progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation. Learn more on Ymmunobio’s website and follow on LinkedIn.
Investor Relations:
Christian Germa, CFO
Contact : chris.p.germa@ymmuno.bio
